NDA 208910 · Azurity
Firvanq Kit
Vancomycin Hydrochloride · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Feb 16, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jan 26, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
501
123 Phase 3, 64 recruiting
FAERS reports
7,489
6,661 serious, 1,458 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 14, 2026.
Vancomycin hydrochloride is indicated for the treatment of Clostridium difficil e‑associated diarrhea in adults and pediatric patients less than 18 years of age. Vancomycin hydrochloride is also indicated for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin‑resistant strains) in adults and pediatric patients less than 18 years of age. Important Limitations of Use Parenteral administration of vancomycin is not effective for the above infections; therefore, vancomycin must be given orally for these infections. Orally administered vancomycin hydrochloride is not effective for treatment of other types of infections. To reduce the development of drug‑resistant bacteria and maintain the effectiveness of vancomycin hydrochloride and other antibacterial drugs, vancomycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Vancomycin hydrochloride is a glycopeptide antibacterial indicated in adults and pediatric patients less than 18 years of age for the treatment of: ( 1 ) Clostridium difficile ‑associated diarrhea Enterocolitis caused by Staphylococcus aureus (including methicillin‑resistant strains) Important Limitations of Use: ( 1 ) ( 5.1 ) Orally administered vancomycin hydrochloride is not effective for treatment of other types of infections. To reduce the development of drug‑resistant bacteria and maintain the effectiveness of vancomycin hydrochloride and other antibacterial drugs,...
Mechanism: Vancomycin is an antibacterial drug [ see Microbiology ( 12.4 ) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 26, 2018 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
2 products under this application
- FIRVANQ KIT · VANCOMYCIN HYDROCHLORIDE EQ 50MG BASE/ML · FOR SOLUTION, ORAL · Prescription · TE AA
- FIRVANQ KIT · VANCOMYCIN HYDROCHLORIDE EQ 25MG BASE/ML · FOR SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Vancomycin" as an intervention, any sponsor and status, largest first.
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over TrialPivotal-lookingNot yet recruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06567808 · 38,000 participants (planned) · Start Mar 1, 2026 · Primary completion Apr 30, 2028
Drug: Cefazolin; Vancomycin · For: Infection, Surgical Site
VA Office of Research and DevelopmentFederal agency
NCT02216227 · 23,005 participants · Start Apr 1, 2014 · Primary completion Feb 28, 2021
Drug: Mupirocin; Chlorhexidine gluconate and 3 more · For: Surgical Site Infection
Sites: Miami, Florida; Iowa City, Iowa; Baltimore, Maryland · 11 sites in all
- Infection Prophylaxis in Total Joint ReplacementPivotal-lookingRecruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06126614 · 21,006 participants (planned) · Start May 7, 2024 · Primary completion Nov 2028
Drug: Chlorhexidine Gluconate; Vancomycin Hydrochloride · For: Periprosthetic Joint Infection
Sites: Hamilton, Canada
- Prevention of Arrhythmia Device Infection Trial (PADIT)Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT01628666 · 12,814 participants · Start Dec 2012 · Primary completion Sep 8, 2017
Drug: Incremental; Conventional · For: Arrhythmia
Sites: Hamilton, Canada
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
- Prevention of Infections in Cardiac SurgeryPivotal-lookingTerminated
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT02285140 · 5,989 participants · Start Apr 2015 · Primary completion Mar 10, 2025
Drug: Cefazolin; Vancomycin · For: Thoracic Surgery; Antibiotic Prophylaxis
Sites: Hamilton, Canada; Toronto, Canada; Montreal, Canada · 4 sites in all
- Prevention of Infections in Cardiac Surgery (PICS) Prevena StudyPivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT03402945 · 4,107 participants · Start Mar 5, 2018 · Primary completion Apr 27, 2023
Drug: Cefazolin; Vancomycin · For: Surgical Site Infections
Sites: Hamilton, Canada; London, Canada
- Simplified Selective Digestive Tract Decontamination for the Prevention of Intensive Care Unit Acquired InfectionsPivotal-lookingStatus unknown
Rambam Health Care CampusAcademic, hospital or other
NCT01798537 · 2,400 participants (planned) · Start Jun 2013 · Primary completion Jul 2015
Drug: Neomycin Colistin Nystatin Vancomycin · For: Bacteremia Associated With Intravascular Line; Ventilator Associated Pneumonia; Bacteremia
Sites: Haifa, Israel
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective856
- acute kidney injury499
- off label use464
- pyrexia437
- rash309
- drug reaction with eosinophilia and systemic symptoms300
- drug hypersensitivity291
- condition aggravated267
- pneumonia266
- diarrhoea263
- sepsis253
- hypotension226
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 61 |
| 2005 | 51 |
| 2006 | 82 |
| 2007 | 150 |
| 2008 | 270 |
| 2009 | 99 |
| 2010 | 91 |
| 2011 | 106 |
| 2012 | 152 |
| 2013 | 196 |
| 2014 | 154 |
| 2015 | 265 |
| 2016 | 160 |
| 2017 | 180 |
| 2018 | 271 |
| 2019 | 452 |
| 2020 | 429 |
| 2021 | 641 |
| 2022 | 921 |
| 2023 | 929 |
| 2024 | 790 |
| 2025 | 671 |
| 2026 | 367 |
Recalls
1 FDA enforcement reports for this application.
Aug 24, 2021 · Class I · Terminated
Product Mix-up: Incorrect diluent component included in the kit.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ, Miller MA, Mullane KM, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Comparative Study
- Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis.
Eichel VM, Last K, Brühwasser C, et al. · J Hosp Infect 2023 · Meta-Analysis, Systematic Review
- Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus.
Kato H, Hagihara M, Asai N, et al. · J Glob Antimicrob Resist 2021 · Meta-Analysis, Systematic Review
- Risk factors for vancomycin-associated acute kidney injury: A systematic review and meta-analysis.
Kim JY, Yee J, Yoon HY, et al. · Br J Clin Pharmacol 2022 · Meta-Analysis, Systematic Review
- Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection : A Randomized Controlled Trial.
Juul FE, Bretthauer M, Johnsen PH, et al. · Ann Intern Med 2025 · Equivalence Trial, Multicenter Study
- The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia.
Chavanet P · Med Mal Infect 2013 · Clinical Trial, Phase IV, Comparative Study
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.